Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy

The present study aimed to compare the differences between the humanized CD19 chimeric antigen receptor (CAR)-T cell therapy and the murine CD19 CAR-T therapy in recurrent B-acute lymphoblastic leukemia (B-ALL). A 62-year-old male patient who had B-ALL (BCR/ABL(+)) for 4 years was diagnosed with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Liu, Mei-Jing, Mou, Nan, Yang, Zhen-Xing, Wang, Jia, Mu, Juan, Zhu, Hai-Bo, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461760/
https://www.ncbi.nlm.nih.gov/pubmed/34584566
http://dx.doi.org/10.3892/ol.2021.13049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461760/
https://www.ncbi.nlm.nih.gov/pubmed/34584566
http://dx.doi.org/10.3892/ol.2021.13049

Ejemplares similares